AR106132A1 - OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES - Google Patents
OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIESInfo
- Publication number
- AR106132A1 AR106132A1 ARP160102913A ARP160102913A AR106132A1 AR 106132 A1 AR106132 A1 AR 106132A1 AR P160102913 A ARP160102913 A AR P160102913A AR P160102913 A ARP160102913 A AR P160102913A AR 106132 A1 AR106132 A1 AR 106132A1
- Authority
- AR
- Argentina
- Prior art keywords
- vegf antibodies
- optimized variants
- variants
- pharmacokinetics
- expression
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anticuerpos anti-VEGF y composiciones que incluyen anticuerpos anti-VEGF (por ejemplo, conjugados de anticuerpos, proteínas de fusión, y formulaciones poliméricas), y usos de los mismos, por ejemplo para el tratamiento de trastornos asociados con la angiogénesis patológica. La presente también proporciona métodos para la identificación de variantes de anticuerpos con propiedades mejoradas, por ejemplo, afinidad de unión incrementada, estabilidad, farmacocinética, y/o expresión.Anti-VEGF antibodies and compositions including anti-VEGF antibodies (for example, antibody conjugates, fusion proteins, and polymer formulations), and uses thereof, for example for the treatment of disorders associated with pathological angiogenesis. This also provides methods for the identification of antibody variants with improved properties, for example, increased binding affinity, stability, pharmacokinetics, and / or expression.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222698P | 2015-09-23 | 2015-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106132A1 true AR106132A1 (en) | 2017-12-13 |
Family
ID=60931773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102913A AR106132A1 (en) | 2015-09-23 | 2016-09-23 | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR106132A1 (en) |
-
2016
- 2016-09-23 AR ARP160102913A patent/AR106132A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018003863A2 (en) | Anti-vegf antibodies | |
| CY1124118T1 (en) | Thymic stroma LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USING THE ANTIBODIES | |
| CL2020003409A1 (en) | Specific binding molecules for cd73 and manufacturing methods of the same (divisional of the application no. 201701154) | |
| MX2018009581A (en) | Fabs-in-tandem immunoglobulin and uses thereof. | |
| MY201701A (en) | Optimized antibody compositions for treatment of ocular disorders | |
| CO2019002609A2 (en) | Recombinant binding proteins and their uses | |
| CY1124806T1 (en) | ENANTI-CD40 ANTIBODIES AND USES THEREOF | |
| CY1123274T1 (en) | ANTI-OX40 ANTIBODIES AND USES THEREOF | |
| CL2024002173A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| CO2017012974A2 (en) | Tau binding antibodies | |
| MX2017003359A (en) | PROTEIN KINASE 2 INHIBITORS ACTIVATED BY PROTEIN KINASE ACTIVATED BY MITOGEN (MK2) AND ITS USES. | |
| BR112019007369A2 (en) | anti-lag-3 antibodies and methods of use | |
| EA201692201A1 (en) | CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7 | |
| BR112019012343A2 (en) | il-11ra antibodies | |
| AR100215A1 (en) | ANTIBODY-DRUG CONJUGATES ANTI-PTK7 | |
| MX421186B (en) | Antibody constructs | |
| CO2017012971A2 (en) | Tau binding antibodies | |
| BR112018012262A2 (en) | Interleukin-15 compositions and their uses | |
| MX2018015272A (en) | Anti-cd98 antibodies and antibody drug conjugates. | |
| MX2018015268A (en) | Anti-cd98 antibodies and antibody drug conjugates. | |
| MX2018015274A (en) | Anti-cd98 antibodies and antibody drug conjugates. | |
| CO2020000369A2 (en) | Polypeptides that bind to the complement component c5 or serum albumin and their fusion proteins | |
| CY1122644T1 (en) | TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, PHARMACEUTICAL FORMS AND THEIR USE | |
| BR112018072118A2 (en) | interferon beta antibodies and their uses |